Frequency-independent blockade of cardiac Na+ channels by riluzole: Comparison with established anticonvulsants and class I anti-arrhythmics

Fundamental and Clinical Pharmacology

Volumn 14, Issue 2, 2000, Pages 107-117

  Mestre, Michel ^a   Djellas, Yasmine ^a,b   Carriot, Thierry ^a   Cavero, Icilio ^a,c  

^a SANOFI   (France)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c NONE   (France)

Author keywords

Anticonvulsants; Cardiac Purkinje fibres; Frequency dependence; Intracardiac conduction; Na+ channel blockade; Riluzole

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; DISOPYRAMIDE; FLECAINIDE; LAMOTRIGINE; LIDOCAINE; LIFARIZINE; PHENYTOIN; RILUZOLE; SODIUM ION;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICONVULSANT THERAPY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG MECHANISM; DRUG SPECIFICITY; FEMALE; GUINEA PIG; HEART ARRHYTHMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SODIUM TRANSPORT;

EID: 0034036946     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2000.tb00398.x     Document Type: Article

References (38)

1. [1] Mizoule J., Meldrum B., Mazadier M., Croucher M., Ollat C., Uzan A. et al., 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission. I. Anticonvulsant properties, Neuropharmacology 24 (1985) 767-773.
2. [2] Malgouris C., Bardot F., Daniel M., Pellis F., Rataud J., Uzan A., Blanchard J.C., Laduron P., Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischaemic gerbils, J. Neurosci. 9 (1989) 3720-3727.
3. [3] Woosley R.L., Antiarrhythmic drugs, Annu. Rev. Pharmacol. Toxicol. 31 (1991) 427-455.
4. [4] Konzen G., Reichardt B., Hauswirth O., Fast and slow blockade of sodium channels by flecainide in rabbit cardiac Purkinje fibres, Naunyn-Schmiedeberg's Arch. Pharmacol. 341 (1990) 565-576.
5. + channels in myelinated nerve fibre, Pflügers Arch. 419 (1991) 603-609.
6. [6] Hebert T., Drapeau P., Pradier L., Dunn R.J., Block of the rat brain IIa sodium channel α subunit by the neuroprotective drug riluzole, Mol. Pharmacol. 45 (1994) 1055-1060.
7. [7] Hubert J.P., Delumeau J.C., Glowinski J., Premont J., Doble A., Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action, Br. J. Pharmacol. 113 (1994) 261-267.
8. [8] Catterall W.A., Common modes of drug action on sodium channels: local anaesthetics, antiarrhythmics and anticonvulsants, Trends Pharmacol. Sci. 8 (1987) 57-65.
9. [9] The Cardiac Arrhythmia Suppression Trial (CAST) investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction, N. Engl. J. Med. 321 (1989) 406-412.
10. [10] Coplen S.E., Antman E.M., Berlin J.A., Hewitt P., Chalmers T.C., Efficacity and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials, Circulation 82 (1990) 1106-1116.
11. [11] Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obiasmanno D., Barker A.H., Mortality and morbidity in patients receiving encainide, flecainide or placebo, N. Engl. J. Med. 324 (1991) 781-788.
12. + currents in differentiated SH-SY5Y cells by lifarizine, Br. J. Pharmacol. 113 (1994) 600-606.
13. [13] Cheung H., Kamp D., Harris E., An in vitro investigation of the action of lamotrigine on neuronal-activated sodium channels, Epilepsy Res. 13 (1992) 107-112.
14. [14] MacDonald R.L., Kelly K.M., Antiepileptic drug mechanisms of action, Epilepsia 34 (suppl. 5) (1993) S1-S8.
15. [15] Matsuki N., Quandt F.N., Ten Eick R.E., Yeh J.Z., Characterization of the block of sodium channels by phenytoin in mouse neuroblastoma cells, J. Pharmacol. Exp. Ther. 228 (1984) 523-530.
16. [16] McGivern J.G., Patmore L., Sheridan R.D., Actions of the novel neuroprotective agent, lifarizine (RS-87476), on voltage-dependent sodium currents in the neuroblastoma cell line, N1E-115, Br. J. Pharmacol. 114 (1995) 1738-1744.
17. + channels as targets for neuroprotective drugs, Trends Pharmacol. Sci. 16 (1995) 309-316.
18. [18] Willow M., Gonoi T., Catterall W.A., Voltage clamp analysis of the inhibitory action of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells, Mol. Pharmacol. 27 (1985) 549-558.
19. [19] Buckley N.A., Whyte I.M., Dawson A.H., Self-poisoning with lamotrigine, Lancet 342 (1993) 1552-1553.
20. [20] Mestre M., Bouetard G., Le Fur G., Renault C., Gueremy C., Uzan A., 1-[4-(2-Ter-butyl-quinolyl)]-3-(4-piperidyl)propanol (PK 10139): a new potent and long-acting antiarrhythmic agent, J. Pharmacol. Exp. Ther. 225 (1983) 158-163.
21. [21] Harris A.S., Delayed development of ventricular ectopic rhythms following coronary artery occlusion, Circulation 1 (1950) 1318-1328.
22. [22] Gintant G.A., Hoffman B.F., Naylor R.E., The influence of molecular form of local anaesthetic-type antiarrhythmic agents on reduction of the maximum upstroke velocity of canine cardiac Purkinje fibers, Circ. Res. 52 (1983) 735-746.
23. [23] Cohen C.J., Bean B.P., Tsien R.W., Maximal upstroke velocity as an index of available sodium conductance. Comparison of maximal upstroke velocity and voltage-clamp measurements of sodium current in rabbit Purkinje fibres, Circ. Res. 54 (1984) 636-651.
24. [24] Pratt J., Rataud J., Bardot F., Roux M., Blanchard J.C., Laduron P.M., Stutzmann J.M., Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia, Neurosci. Lett. 140 (1992) 225-230.
25. Na in canine cardiac Purkinje cells, Circ. Res. 63 (1988) 386-398.
26. [26] Bohme G.A., Le Guern S., Boudeau P., Randle J.C.R., Riluzole: frequency-dependent actions link inhibition of sodium channels and inhibition of synaptic transmission, 24th Meeting of the Society for Neuroscience, Miami, USA, (1994) Abstract 624.11.
27. [27] Sanchez-Chapula J., Josephson I.R., Effect of phenytoin on the sodium current in isolated rat ventricular cells, J. Mol. Cell. Cardiol. 15 (1983) 515-522.
28. max reduction by class I antiarrhythmic agents: relation to frequency dependence, Drug Dev. Res. 24 (1991) 167-177.
29. [29] Sheu S.S., Lederer W.J., Lidocaine's negative inotropic and antiarrhythmic actions. Dependence on shortening of action potential duration and reduction of intracellular sodium activity, Circ. Res. 57 (1985) 578-590.
30. [30] Harrison D.C., Antiarrhythmic drug classification: New science and practical applications, Am. J. Cardiol. 56 (1985) 185-187.
31. max of action potential upstroke in canine cardiac Purkinje fibers, J. Cardiovasc. Pharmacol. 7 (1985) 482-492.
32. max) in guinea-pig ventricular action potentials by mexiletine, disopyramide and encainide, J. Cardiovasc. Pharmacol. 5 (1983b) 291-296.
33. [33] Ehring G.R., Moyer J.W., Hondeghem L.M., Quantitative structure-activity studies of antiarrhythmic properties in a series of lidocaine and procainamide derivatives, J. Pharmacol. Exp. Ther. 244 (1988) 479-492.
34. [34] Vaughan Williams E.M., A classification of antiarrhythmic actions reassessed after a decade of new drugs, J. Clin. Pharmacol. 24 (1984) 129-147.
35. [35] Hondeghem L.M., Katzung B.G., Time-and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels, Biochim. Biophys. Acta 472 (1977) 373-398.
36. max) of action potential in guinea-pig cardiac muscles, J. Mol. Cell. Cardiol. 19 (1987) 367-377.
37. [37] Meldrum B.S., Lamotrigine - a novel approach, Seizure 3 (suppl. A) (1994) 41-45.
38. [38] Catterall W.A., Cellular and molecular biology of voltage-gated sodium channels, Physiol. Rev. 72 (1992) S15-S48.